---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-131410"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2021-10-29T23:59:59+00:00"
generated_at: "2026-06-28T16:09:15.864564+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# iRadimed Q3 revenue up 42% to $10.9M; raises full-year guidance

## Summary
- Q3 2021 revenue $10.9M (+42% YoY); GAAP diluted EPS $0.20, non-GAAP $0.23.
- Full-year 2021 guidance raised: revenue $41.4-41.6M, GAAP EPS $0.60-0.61, non-GAAP $0.70-0.71.
- Gross profit margin improved to 77.1% from 74.6% in Q3 2020; domestic sales 79.5% of revenue.
- Nine-month operating cash flow $7.9M vs $3.3M; free cash flow $7.5M vs $3.0M.

## SEC filing metadata
- accession: 0001104659-21-131410
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2021-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000110465921131410/0001104659-21-131410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000110465921131410/tm2131304d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-131410
- JSON: https://secwatch.observer/filing/0001104659-21-131410.json
- Plain text: https://secwatch.observer/filing/0001104659-21-131410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.